These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1481 related articles for article (PubMed ID: 33734704)

  • 1. Macrolides May Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Entry into Cells: A Quantitative Structure Activity Relationship Study and Experimental Validation.
    Galvez J; Zanni R; Galvez-Llompart M; Benlloch JM
    J Chem Inf Model; 2021 Apr; 61(4):2016-2025. PubMed ID: 33734704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrolide treatment for COVID-19: Will this be the way forward?
    Ohe M; Shida H; Jodo S; Kusunoki Y; Seki M; Furuya K; Goudarzi H
    Biosci Trends; 2020 May; 14(2):159-160. PubMed ID: 32249257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.
    Park SB; Irvin P; Hu Z; Khan M; Hu X; Zeng Q; Chen C; Xu M; Leek M; Zang R; Case JB; Zheng W; Ding S; Liang TJ
    mBio; 2022 Feb; 13(1):e0323821. PubMed ID: 35012356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
    Hosoki K; Chakraborty A; Sur S
    J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.
    Boytz R; Słabicki M; Ramaswamy S; Patten JJ; Zou C; Meng C; Hurst BL; Wang J; Nowak RP; Yang PL; Sattler M; Stone RM; Griffin JD; Gray NS; Gummuluru S; Davey RA; Weisberg E
    J Med Virol; 2023 Jan; 95(1):e28157. PubMed ID: 36117402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Zhang C; Zhou C; Shi L; Liu G
    Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit receptor binding and viral replication.
    Artman C; Brumfield KD; Khanna S; Goepp J
    PLoS One; 2021; 16(5):e0252399. PubMed ID: 34048457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
    Braun J; Loyal L; Frentsch M; Wendisch D; Georg P; Kurth F; Hippenstiel S; Dingeldey M; Kruse B; Fauchere F; Baysal E; Mangold M; Henze L; Lauster R; Mall MA; Beyer K; Röhmel J; Voigt S; Schmitz J; Miltenyi S; Demuth I; Müller MA; Hocke A; Witzenrath M; Suttorp N; Kern F; Reimer U; Wenschuh H; Drosten C; Corman VM; Giesecke-Thiel C; Sander LE; Thiel A
    Nature; 2020 Nov; 587(7833):270-274. PubMed ID: 32726801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
    Nandi S; Roy H; Gummadi A; Saxena AK
    Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
    Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
    J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of L-Type Calcium Channels Show Therapeutic Potential for Treating SARS-CoV-2 Infections by Preventing Virus Entry and Spread.
    Straus MR; Bidon MK; Tang T; Jaimes JA; Whittaker GR; Daniel S
    ACS Infect Dis; 2021 Oct; 7(10):2807-2815. PubMed ID: 34498840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.